The firm is on track to launch the gene therapy for dystrophic epidermolysis bullosa, called Vyjuvek in the US, in Germany in Q2 2025.

CHMP opinion now expected in 1Q 2025No Major Objections outstanding; continue to expect Germany launch in 2Q 2025PITTSBURGH, Dec. 09, 2024 ...

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further ...

Krystal Biotech (KRYS) announced that the European Medicines Agency’s, or EMA’s, Committee for Medicinal Products for Human Use, or CHMP, ...

H3 demethylation that modulates MKP-1/MAPK signaling may account for the long-term inhibitory effect of prenatal dexamethasone exposure on osteoprogenitor proliferation and the consequent ...

In severe cases, such as Recessive Dystrophic EB, bandage changes to protect wounds and prevent blister infection are required every day and can last three to four hours at a time. The two-year ...

Vlahovic highlighted several options that can help improve the appearance of dystrophic nails as they recover or grow back: In Vlahovic's experience, KeryFlex and NECPro last 6-8 weeks.

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

A resubmission Biologics License Application for prademagene zamikeracel (pz-cel) as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted by the FDA, according ...